Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

This study has been completed.

Study NCT00025415 Information provided by National Cancer Institute (NCI)

First Received: October 11, 2001 Last Updated: June 4, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP; National Cancer Institute Organ Dysfunction Working Group. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008 Feb 1;26(4):563-9.

Ramanathan RK, Remick SC, Mulkerin D, et al.: P-5331: a phase I pharmacokinetic (PK) study of STI571 in patients (pts) with advanced malignancies and varying degrees of liver dysfunction (LD). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-502, 2003.